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the initial palliative operative period. The dominant
issue in the patient’s long-term course often becomes
subsequent prosthesis replacements.
Previous studies1-4 have evaluated factors associated
with freedom from reoperation for pulmonary valve
replacement. Factors commonly reported as important
are valve type and size, age of patient, and diagnosis.
Many studies, however, are limited to a single valve
type (eg, allografts) and attempt to identify important
predictors for valve survival within the context of the
particular valve type being studied. For the surgeon to
choose between different types of valve prostheses for
an individual patient, however, he or she must compare
the results of these disparate studies to arrive at the opti-
mum choice. Comparison between studies limited to a
single valve type is problematic in that patient selection
bias and institution-related factors may limit the ability
to make valid comparisons.
Comparison among studies limited to a single valve
type can also be problematic because age is frequent-
P lacement of a valve or valved conduit in the pul-monary circulation during repair of congenital heart
defects is problematic in that most of these prostheses
will eventually require replacement. Therefore, conse-
quences of the choice of prosthesis extend far beyond
Objective: To evaluate the age dependence of variables predictive of pul-
monary valve prosthesis replacement, we conducted the following analysis.
Methods: Retrospective analysis of 945 operations in 726 patients undergo-
ing placement of pulmonary valve prostheses was performed. Age was iden-
tified as a strong independent predictor of valve failure. The database was
stratified into age-based subsets and predictors of valve replacement were
identified within each subset.
Results: For the entire cohort, freedom from valve replacement at 5 years was
81%. Younger age was strongly associated with decreased time to valve
replacement by multivariable analysis (hazard ratio: 0.71/log-year, P < .001).
Other independent factors included diagnosis, type of prosthesis, and time-
dependent requirement for pulmonary valve stent placement. Important pre-
dictors of valve failure varied among age groups and are as follows: for age
less than 3 months: valve type; for age 3 months to less than 2 years: small-
er normalized valve prosthesis size; for age 2 years to less than 13 years:
sex, smaller normalized valve prosthesis size, placement of endovascular
stents, and valve type; for age 13 years to 65 years: smaller normalized valve
prosthesis size, placement of endovascular stents, and increased number of
previous valve placements.
Conclusion: Age is a dominant risk factor predictive of pulmonary valve
prosthesis failure. A significant interaction exists between age and the effects
of diagnosis, valve type, and size on prosthetic pulmonary valve longevity.
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ly an important predictor of valve survival.1,4-6
Inasmuch as the age of the cohort studied often varies
between studies, it may be inappropriate to make
direct comparisons between such studies. For exam-
ple, a study of allografts in children (median age 6.5
years) by Weipert and associates7 is difficult to com-
pare with a study in children (median age 14 years) by
Niwaya and associates.6
With these difficulties in mind, we sought to explore
the relationship between age and freedom from pul-
monary valve prosthesis replacement in a large single-
institution database encompassing a wide spectrum of
valve types and a broad age range. Our first step in the
analysis was to define the relationship between age and
freedom from valve replacement and to confirm the sta-
tistical significance of this relationship. This would
then allow us to approach our primary objective, which
was to explore the variation in predictors of valve sur-
vival across clinically relevant age-based strata.
Methods
Study population. We examined the records of all patients
undergoing placement of a valve or valved conduit in the pul-
monary circulation for congenital heart disease between June
1966 and December 1996 using the combined database of
The Hospital for Sick Children/Toronto Congenital Cardiac
Centre for Adults. A total of 726 patients undergoing 945
operations were identified. Choice of conduits was at the dis-
cretion of the surgeon but was restricted by size of the patient
and availability of allografts of appropriate size.
Patient follow-up was obtained through review of medical
records, clinic visits, and direct telephone contact. Follow-up
was considered complete if the patient’s status was deter-
mined after June 1997. The median duration of follow-up was
8.3 years (range birth to 31.5 years) and 93% of survivors had
complete follow-up.
Valve survival. Valve survival is defined as the interval
between implantation of a device in the pulmonary circula-
tion and the date of reoperation for valve replacement.
Patients not requiring valve replacement were treated as cen-
sored events at the time of last clinical contact or the death of
the patient. Because many patients had multiple valve
replacements, the same patient may have provided data for
more than one interval. Each valve survival interval was treat-
ed as an independent event.
Pulmonary valve sizes. So that valve sizes could be com-
pared across a broad range of age groups, the predicted pul-
monary anulus size was calculated according to the data of
Rowlatt, Rimoldi, and Lev.8 The size of the valve prosthesis
was then compared with the predicted pulmonary anulus size,
and a z-score was developed that described the number of
standard deviations between the size of the pulmonary valve
prosthesis and the predicted average pulmonary anulus diam-
eter.
Data analysis. Data are described as frequencies, medians
with ranges, or means with standard deviations as appropri-
ate. The Cox proportionate hazard modeling was used to
determine both univariable and multivariable relationships
between time to reintervention for conduit or valve replace-
ment and explanatory variables. SAS Version 6.12 statistical
software (SAS Institute, Inc, Cary, NC), set to default set-
tings, was used to perform all statistical analyses.
Results
Study population. The median age of the entire
cohort is 6.2 years (range 1 day–65 years). General
characteristics of the population are summarized in
Table I. Approximately 25% of the patients underwent
at least two pulmonary valve placement procedures.
The devices implanted were grouped into three major
categories (allograft, pericardial, and porcine) and two
minor categories (Polystan conduits [Polystan A/S,
Copenhagen, Denmark] and miscellaneous). The mis-
Table I.  Type of valve prosthesis stratified by number of previous prosthesis placements
Valve prosthesis placement
Valve type used First Second Third or more Total
Allograft (n = 396) Aortic 141 23 3 167
Pulmonary 176 44 9 229
Pericardial (n = 112) Ionescu-Shiley 58 5 0 63
Mitroflow 34 12 3 49
Porcine (n = 343) Carpentier-Edwards 83 30 5 118
Hancock 145 50 14 209
Medtronic Intact 14 2 0 16
Polystan (n = 79) Polystan 67 11 1 79
Other (n = 15) 8 6 1 15
Totals 726 183 36 945
Manufacturers: Shiley, Inc, Irvine, California; Sulzer Mitroflow Corporation, Richmond, British Columbia, Canada; Baxter Healthcare Corporation, Edwards
Division, Santa Ana, California; Medtronic, Inc, Minneapolis, Minnesota; Polystan A/S, Copenhagen, Denmark.
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cellaneous category (“other”) included any valve type
used in 4 or fewer patients. The choice of valve pros-
thesis varied across the age range of the cohort. In gen-
eral, homografts were most commonly used in the
youngest patients and porcine valves were most com-
monly used in the older patients (Fig 1, A). 
The techniques used for valve placement varied with
age. Valved conduits were commonly used in the
younger patient groups in which discontinuity of the
ventriculopulmonary connection was more frequently
present (eg, truncus arteriosus). In contrast, in the older
age groups, in which continuity between the heart and
pulmonary arteries was more frequently present (eg,
tetralogy of Fallot with pulmonary insufficiency),
orthotopically placed pulmonary valve implants3 were
used with increasing frequency (Fig 1, B).
The indications for replacement of a failed pul-
monary valve prosthesis are summarized in Fig 2. The
majority of replacements were associated with some
degree of stenosis. The clinical threshold for consider-
ation of prosthesis replacement can be expected to have
varied between individual patients over the study peri-
od. In general, a right ventricular systolic pressure
greater than 60% of the systemic pressure or, in the
presence of pulmonic insufficiency, increasing right
ventricular dimensions, arrhythmias, or onset of tricus-
pid insufficiency were considered indications for
replacement of a pulmonary valve prosthesis.
The diagnostic categories of the patients undergoing
initial pulmonary valve or valved conduit replacement
are summarized in Table II. Pulmonary atresia with
ventricular septal defect, truncus arteriosus, and tetral-
ogy of Fallot were the most common diagnoses, com-
prising almost 60% of the patients. Allografts were
most frequently used in patients with pulmonary atre-
sia and ventricular septal defect and in those with trun-
cus arteriosus. Pericardial valves were most frequently
used in patients with tetralogy of Fallot. Porcine valve
use was more evenly distributed among patients with
tetralogy, truncus, and transposition of the great arter-
ies. Finally, use of the Polystan conduit was generally
limited to patients with double-outlet right ventricle,
pulmonary atresia, and truncus arteriosus.
Fig 1. A, The graph demonstrates the relative distribution of valve types used as a function of age at surgery.
Homografts are the most commonly used valves in the younger patients and porcine valves are most commonly
used in the older patients. B, The relative distribution of valve placement techniques is plotted as a function of age
at surgery. The use of valved conduits predominates in the younger patients. In contrast, as patient age increases,
the use of the pulmonary valve implant (PVI) technique increases in frequency.
A B
Fig 2. The percentage of prosthesis replacements with a
given indication are plotted. Note that an individual patient
may have multiple diagnoses at the time of prosthesis
replacement (eg, stenosis and insufficiency). “Other surgery”
signifies patients in whom a prosthesis was replaced expec-
tantly as a secondary portion of a separate cardiac procedure. 
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Fig 3 shows a plot of Kaplan-Meier estimates of free-
dom from valve replacement (deaths were censored).
The freedom from valve replacement at 5 years is 82%;
at 10 years, 58%; and at 15 years, 41%. In Cox propor-
tionate hazard modeling, factors associated with a
decreased time to valve replacement were sought first
in univariable analysis (Table III). Significant factors in
univariable analysis of the entire database included
younger patient age at surgery, some cardiac diagnoses,
second procedures (first replacement of a failed pros-
thesis), some prosthesis types, and the need for
endovascular stent implantation. Nonsignificant factors
in the univariable analysis of the entire database includ-
ed sex, date of valve implantation, and decreasing pul-
monary valve prosthesis z-score. 
Effect of age at surgery on time to valve replace-
ment. Younger age at surgery appeared to be strongly
associated with a reduced time to valve replacement in
both univariable and multivariable analyses. The rela-
tionship also appeared to be nonlinear. This relation-
ship was further explored by categorizing the variable
age at surgery into groups of about 50 procedures each.
These variables were then entered as dummy variables
into a final multivariable Cox proportionate hazard
model controlling for sex, pulmonary valve prosthesis
z-score, cardiac diagnosis, and the time-dependent use
of endovascular stents. The age category 15 to 18 years
was used as the reference category, and the parameter
estimates were converted to hazard ratios. Fig 4 is a
plot of the hazard ratios and again shows the nonlinear
risk relationship with time to valve replacement. 
The dominance of age as a risk factor for valve
replacement in the younger age groups is graphically
represented in Fig 4. The adjusted plot takes into
account the contribution of sex, cardiac diagnosis,
valve type, pulmonary valve z-score, and valve type in
the multivariable Cox proportionate hazard modeling.
The effect of adjusting for these other variables has a
relatively small effect on the hazard ratio, most notably
in the younger patients.
Age-stratified analysis. On the basis of the relation-
ships shown in Fig 4, the knowledge that some of the
risk factors were not present in some age groups, and
an interest in which risk factors predominated in which
age groups (interaction), we divided the study popula-
tion into 4 age categories and performed a stratified
analysis of time to valve replacement. The age cate-
gories were less than 3 months (n = 122), 3 months to
less than 2 years (n = 107), 2 years to less than 13 years
(n = 456), and 13 to 65 years (n = 260). These cate-
gories were chosen on the basis of knowledge about the
distribution of risk variables and the magnitude of the
hazard ratios across the smaller age categories, as noted
in Fig 4, with smaller categories with similar hazard
ratios being grouped together. Results of this analysis
are given in Table IV.
Age less than 3 months at surgery. For the 122 pro-
cedures, the median age at surgery was 17 days. The
unadjusted hazard ratio for risk of valve failure relative
to all other age categories was 4.02 (95% confidence
limits [CL]: 2.73-5.93). All implants were the initial
procedure. Truncus arteriosus in 92 patients was the
predominant diagnosis, with pulmonary atresia with
ventricular septal defect in 10 and a heterogeneous
group of other lesions in 20 patients. Valve type
implanted included aortic homograft conduits in 44
patients, pulmonary homograft conduits in 33, Polystan
conduits in 22, porcine valved conduits in 17, and other
Table II. The type of valve prosthesis is tabulated against diagnosis
Number of prostheses used per each diagnosis
Primary diagnosis No. % Allograft Pericardial Porcine Polystan Other
PA/VSD 185 19.6 110 11 44 15 5
Truncus arteriosus 173 18.3 94 2 46 29 2
ToF 168 17.8 33 50 75 8 2
D-TGA 100 10.6 40 1 53 6 0
L-TGA 95 10.1 38 0 52 4 1
ToF/absent PV 85 9.0 27 23 28 4 3
DORV 65 6.9 27 3 23 12 0
Other 28 3.0 17 3 8 0 0
PS 23 2.4 6 7 7 1 2
PA/IVS 20 2.1 4 12 4 0 0
Tricuspid atresia 3 0.3 0 0 3 0 0
Total 945 100.0 396 112 343 79 15
PA/VSD, Pulmonary atresia with ventricular septal defect; ToF, tetralogy of Fallot; TGA, transposition of the great arteries; PV, pulmonary valve; DORV, double-out-
let right ventricle; PS, pulmonic stenosis; PA/IVS, pulmonary atresia with intact ventricular septum.
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types in 6 patients. In the univariable Cox proportion-
ate hazard modeling, time to valve replacement was not
significantly related to age and sex, date of surgery,
cardiac diagnosis, pulmonary valve prosthesis z-score,
or the time-dependent use of endovascular stents. Time
to valve replacement was significantly related only to
valve type (P = .04), with hazard ratios as follows: pul-
monary homograft conduit (reference category); aortic
homograft conduit, 1.59; porcine valved conduit, 4.08;
Polystan valved conduit, 5.42; and other types, 0.76.
Age 3 months to less than 2 years at surgery. For the
107 procedures, the median age at surgery was 11.3
months. The unadjusted hazard ratio for risk of valve
failure relative to all other age categories was 2.59
(95% CL: 1.78-3.75). Truncus arteriosus (n = 36) and
pulmonary atresia with ventricular septal defect (n =
33) were the predominant cardiac diagnoses, and
valved conduits (mainly homografts) were the predom-
inant valve type. The only variable significantly associ-
ated with a reduced time to valve replacement was a
smaller pulmonary valve prosthesis z-score (P = .02),
with a hazard ratio of 0.75 per 1 standard deviation
increment.
Age 2 years to less than 13 years at surgery. For the
456 procedures, the median age at surgery was 6.0
years. The unadjusted hazard ratio for risk of valve fail-
ure relative to all other age categories was 1.54 (95%
CL: 1.19-2.00). Pulmonary atresia with ventricular
septal defect (n = 121), tetralogy of Fallot (n = 74), and
transposition of the great arteries (n = 62) were the pre-
dominant cardiac diagnoses. Porcine valved conduits
(n = 111), pulmonary homograft conduits (n = 111),
aortic homograft conduits (n = 69), and pericardial
valves (n = 66) were the predominant valve types.
Significant factors in univariable analysis associated
with a reduced time to valve replacement included
male sex (P = .04; hazard ratio 1.41), smaller pul-
monary valve prosthesis z-score (P = .04; hazard ratio
0.93 per 1 standard deviation increment), the time-
dependent use of endovascular stents (P = .02; hazard
ratio 2.02), and valve type (P = .008). Hazard ratios for
valve type are as follows: pulmonary homograft con-
duit, reference category (1.00); porcine valved implant,
1.12; pericardial valve implant, 1.70; aortic homograft
conduit, 1.87; homograft valve implant, 1.97; porcine
valved conduit, 2.00; and Polystan valved conduit,
3.50. Time to valve replacement was not significantly
related to age or date of surgery, cardiac diagnosis, or
number of procedure.
Age 13 to 65 years at surgery. For the 260 proce-
dures, the median age was 19 years. The unadjusted
hazard ratio for risk of valve failure relative to all other
age categories was 0.19 (95% CL: 0.12-0.28).
Tetralogy of Fallot (n = 80), ventricular inversion (L-
transposition of the great arteries, n = 45), and transpo-
sition of the great arteries (n = 34) were the predomi-
nant cardiac diagnoses. Porcine valved conduits (n =
97), porcine valved implants (n = 62), and pericardial
valve implants (n = 38) were the predominant valve
types. The procedure was the second procedure in 82
patients and the third or more procedure in 21 patients.
Time to valve replacement was significantly related to
the number of the procedure (P < .001), with hazard
ratios relative to an initial procedure (reference catego-
Fig 3.  Kaplan-Meier estimates of freedom from valve replacement. Vertical lines represent 95% confidence inter-
vals. The freedom from valve replacement at 5 years is 82%, at 10 years is 58%, and at 15 years is 41%.
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ry) for second procedures of 0.55 and for third or
greater procedures of 8.76. Reduced time to valve
replacement was also related to smaller pulmonary
valve prosthesis z-score (P = .01; hazard ratio 0.83 per
1 standard deviation increment), and the time-depen-
dent use of endovascular stents (P < .001; hazard ratio
31.0). Time to valve replacement was not significantly
related to sex, age, date of surgery, cardiac diagnosis, or
valve type.
Discussion
Use of a valve or valved conduit to create continuity
between the ventricle and pulmonary circulation has
become an integral part of the surgical therapy for
many complex congenital heart lesions. The valve pros-
thesis used in such therapy, however, has been
described as a “weak facet” of reconstructive surgery
because of the inevitable need for its replacement.4 In
choosing a valve prosthesis for a patient, the surgeon
must assimilate data from numerous series with limit-
ed similarities in patient ages, diagnoses, and types of
devices studied. On the basis of this information, the
surgeon must select the valve prosthesis most likely to
provide the greatest durability and, thus, freedom from
reoperation.
In the present study, the experience at a single insti-
tution has been analyzed to identify predictors of pul-
monary valve prosthesis failure. The breadth of the
cohort in terms of valve prosthesis types, implantation
techniques (pulmonary valve implant or conduit), and
diagnoses across an age range of 65 years provides
some advantages in the statistical analysis. Specifically,
Table III. Associations between explanatory variables and time to valve or valved conduit replacement
Univariable analysis Multivariable analysis
Variable Estimate SE Hazard ratio P value Estimate SE Hazard ratio P value
Sex
Male Reference category Reference category
Female –0.1090 0.1276 0.90 .40 –0.1856 0.1383 0.83 .18
Age at surgery (log-y) –0.3386 0.0295 0.71 <.001 –0.3455 0.0473 0.71 <.001
Cardiac diagnosis
ToF Reference category Reference category
Pulmonary atresia/VSD 1.0194 0.2393 2.77 <.001 0.7843 0.2623 2.19 .003
Truncus arteriosus 1.4680 0.2466 4.34 <.001 0.5668 0.3235 1.76 .08
D-TGA 0.9765 0.2528 2.66 <.001 0.9566 0.2872 2.60 <.001
L-TGA 0.6882 0.2632 1.99 .009 0.8468 0.2934 2.33 .004
ToF/absent PV 0.6245 0.2642 1.87 .02 0.5528 0.2802 1.74 <.05
DORV 1.3296 0.2833 3.78 <.001 1.2720 0.3073 3.57 <.001
Critical PV stenosis 0.0942 0.5370 1.10 .87 0.0304 0.5487 1.03 .96
PA/IVS 0.8032 0.4240 2.23 .06 0.6427 0.4390 1.90 .15
Other type of anomaly 0.6377 0.4861 1.89 .19 0.6900 0.4944 1.99 .17
Date of surgery (per consecutive 5 years) 0.0640 0.0621 1.07 .30 0.0132 0.0818 1.01 .88
Procedure number
Initial Reference category Reference category
Second –0.3804 0.1852 0.68 .04 –0.1717 0.2047 0.84 .41
Third greater 0.1671 0.3414 1.18 .69 0.3525 0.3752 1.42 .35
PV prosthesis z-score* –0.0552 0.0295 0.95 .06 –0.0396 0.0329 0.96 .23
Prosthesis type
PV homograft conduit Reference category Reference category
AV homograft conduit 0.6349 0.2062 1.89 .002 0.6003 0.2105 1.82 .005
PV or AV homograft implant† 0.1350 0.3311 1.15 .69 0.7924 0.3896 2.21 <.05
Porcine valve conduit 0.1375 0.1971 1.15 .49 0.5867 0.2280 1.80 .02
Porcine valve implant –0.7159 0.3865 0.49 .07 0.4630 0.4323 1.59 .29
Polystan valved conduit 1.2001 0.2181 3.32 <.001 1.2204 0.2370 3.39 <.001
Pericardial valve implant –0.2113 0.2387 0.81 .79 0.6404 0.2970 1.90 .04
Endovascular stent implantation‡ 1.2625 0.1981 3.53 <.001 0.6034 0.2335 1.83 .01
SE, Standard error; ToF, tetralogy of Fallot; VSD, ventricular septal defect; TGA, transposition of the great arteries; PV, pulmonary valve; DORV, double-outlet right
ventricle; PA/IVS, pulmonary atresia with intact ventricular septum; AV, aortic valve.
*Based on predicted pulmonary valve anulus based on patient’s body surface area.
†Implant refers to placement of a valve prosthesis in the orthotopic position without a conduit.
‡Entered as time-dependent explanatory variable.
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a multivariable analysis of the entire cohort examining
the associations between explanatory variables predic-
tive of valve failure was possible. Age, diagnosis, type
of valve prosthesis, and endovascular stent placement
are associated with prosthesis longevity.
The information regarding risk factors, however, is of
limited value to the surgeon faced with the dilemma of
choosing the optimum valve prosthesis for an individ-
ual patient. Of the important variables identified, age
and diagnosis cannot be changed. The choice of pros-
thesis, however, can be modified, and the data derived
from analyzing the entire cohort suggest that pul-
monary homograft conduits and possibly porcine
valved implants are associated with the longest times to
valve or valved conduit replacement. The hazard ratios
for other valve prostheses in this population were
greater than 1.5 when compared with pulmonary
homograft conduits.
We are reluctant, however, to accept this interpreta-
tion at face value due to the important influence of
age on freedom from valve replacement. As noted in
Fig 4, the addition of other variables to the analysis
had a very small effect on freedom from valve
replacement when compared with age alone.
Precisely because the age range is so broad in this
cohort and because the influence of age varies so dra-
matically across the age spectrum, the concern that
the influence of other variables may be important in
smaller age subsets is raised. Also, the distribution of
the other variables was not homogeneous throughout
the age range (eg, porcine valve use was skewed to
older age groups as illustrated in Fig 1, A). A com-
plete description of the interaction between age and
these other inhomogeneously distributed variables is
extremely complex. We chose, instead, to stratify the
cohort in a compromise for clarity, albeit with
reduced statistical power within each age stratum.
In the clinical arena, an infant may be expected to
have different mechanisms of valve failure from those
of an adult. Indeed, previous studies have noted that
homograft degeneration is accelerated in younger
patients, possibly due to age-related immune mecha-
nisms.9,10 Others have noted age-related histologic pat-
terns in failed homografts.11 It is not surprising, there-
fore, that different predictors of valve survival may be
operative to a greater or lesser degree in different age
strata. In the present study, univariable analysis of vari-
ables associated with time to valve failure derived dif-
ferent results among the age strata. If an independent
investigation was conducted within each age group,
different conclusions could be raised. This finding sup-
ports the notion that comparison of studies with differ-
Table IV.  Predictors of valve prosthesis failure by age-based strata
Age group Variable Hazard ratio P value
<3 mo (n = 122) Valve type .04
Pulmonary homograft conduit 1.0
Aortic homograft conduit 1.59
Porcine valved conduit 4.08
Polystan valved conduit 5.42
“Other” valve types 0.76
3 mo to <2 y (n = 107) Smaller pulmonary valve prosthesis z-score 0.75/SD increment .02
2 y to <13 y (n = 456) Male sex 1.41 .04
Smaller pulmonary valve prosthesis z-score 0.93/SD increment .04
Endovascular stent placement 2.02 .02
Valve type .008
Pulmonary homograft 1.00
Porcine valved implant 1.12
Aortic homograft conduit 1.87
Polystan valved conduit 3.50
Homograft valve implant 1.97
Pericardial valve implant 1.70
Porcine valved conduit 2.00
13 y to 65 y (n = 260) Procedure number: .001
First pulmonary valve 1.00
Second pulmonary valve 0.55
Third pulmonary valve 8.76
Smaller pulmonary valve prosthesis z-score 0.83/SD increment .01
Endovascular stent placement 31.0 .001
SD, Standard deviation. 
the age of the populations studied. More precise identi-
fication of the important variables predictive of valve
survival within different age strata will shed light on
the mechanisms operating within the age strata and
ultimately will improve the surgeon’s ability to decide
which size and type of valve or valved conduit to use in
individual patients.
We thank Derek Stephens, MSc, for his assistance with this
investigation.
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ent age ranges may be problematic when defining vari-
ables predictive of valve failure. 
In the present study, the use of valve replacement as
an indicator of valve failure may be imprecise. A valve
prosthesis may become stenotic or insufficient without
requiring replacement, thereby representing an
echocardiographic failure for a period of time before
replacement.10 Valve insufficiency or stenosis may be
poorly tolerated in a neonate with pulmonary hyperten-
sion, mandating early intervention, but relatively well
tolerated in older patients and not necessitating inter-
vention. Consequently, use of reoperation as the sole
end point for valve failure may fail to detect important
valve dysfunction in older patients. Echocardiographic
detection of valve dysfunction may be a more sensitive
end point when attempting to discriminate between the
“life span” of valve prostheses in older age groups.
In the present study, the placement of an endovascular
stent was used as an explanatory variable rather than an
end point for prosthesis failure. This decision was based
on data from this institution suggesting that approxi-
mately 50% of patients undergoing stent placement were
free of surgical reintervention at 4 years.12  Con-
sequently, the threshold for intervention for stent place-
ment was believed to be somewhat different from the
threshold for surgical intervention; therefore, the vari-
ables predictive of prosthesis replacement are likely to
differ from variables predictive of stent placement. 
Death is used as an end point in some studies evalu-
ating valve prostheses.13 In the present study, we cen-
sored deaths for the following reasons. First, early
deaths (eg, <30 days) are unlikely to be caused by
degeneration of valve prosthesis function, the end point
most commensurate with the objectives of this study.
Consequently, the number of deaths due to other caus-
es can be expected to be far greater than the number of
deaths due to prosthesis failure in the early postopera-
tive period; therefore, the predictors of early death are
likely to be different from predictors of valve prosthe-
sis failure. Late deaths are relatively uncommon events
in this study and are commonly due to causes other
than valve prosthesis failure.2,4
In conclusion, there is a strong relationship between
age and failure of pulmonary valve prostheses. Age-
stratified analysis shows that significant predictors of
valve survival vary among clinically relevant age
groups. Although analysis of the database subsets
results in loss of statistical power, the method allows
identification of changing patterns of predictive vari-
ables across the age spectrum. Consequently, compari-
son between studies of valve survival in the literature
are problematic if even small differences are present in
Fig 4. Adjusted and unadjusted hazard ratios for time to valve
replacement based on age at surgery (from multivariable Cox
proportionate hazard modeling; variables adjusted for in the
model include sex, cardiac diagnosis, valve type, pulmonary
valve prosthesis z-score, and valve type). The vertical axis
represents the hazard ratio for risk of valve failure with a ref-
erence category of 15 to 18 years of age.
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Discussion
Dr Richard A. Jonas (Boston, Mass). This report must be
one of the largest series ever, encompassing 945 operations in
726 patients over a 30-year time frame. Other outstanding
characteristics include the wide range of patient ages at
surgery and the use of several different types of conduits. A
report of this degree of complexity requires highly sophisti-
cated statistical analysis, which Dr McCrindle, a pediatric
cardiologist and statistician with great expertise in this area,
has indeed brought to bear on the problem. 
The most obvious but perhaps also the most predictable
finding of your study is that young age at the time of conduit
implantation is overwhelmingly the most important predictor
of conduit durability. Also not surprising is the finding that a
smaller normalized conduit size is associated with need for
earlier replacement. In children under 13 years of age, pul-
monary homografts tended to be the best choice of conduit,
whereas in older children the type of conduit did not affect
conduit durability. The results of the study do not challenge
currently held beliefs, but rather support them. 
Overall, however, the performance of conduits remains
suboptimal, and it is important to continue to explore meth-
ods for avoiding conduits in young children, or at least meth-
ods for incorporating growth potential in the conduits. I am
hoping that your analysis of this extensive series may have
provided you with insights into some continuing questions
regarding conduits that you have briefly mentioned.
Some of these questions are as follows: What should be the
indication for conduit replacement? We are all aware that
right ventricular outflow obstruction is remarkably well tol-
erated for many years. After all, the atrial switch experience
with transposition has demonstrated that the right ventricle
can work at systemic pressure in the majority of patients for
decades. What were the usual indications in this series for
conduit replacement? Was it 75% systemic pressure, 90%, or
100% systemic pressure? How did the coexistence of pul-
monary regurgitation influence the decision to replace the
conduit? How important is an assessment of right ventricular
volume in making this decision, and how do you presently
assess right ventricular volume in your patients with conduits
to help you with this decision? 
Many of your patients had orthotopic pulmonary valve
replacements after tetralogy repair. If a patient has had a
transannular patch repair of tetralogy, placement of a valve
in the right ventricular outflow tract, on the basis of your
data, will necessitate future reoperations. What should be
the criteria for placement of an orthotopic pulmonary
valve? Should they differ from the indications for conduit
replacement in a patient in whom some form of conduit
connection from the right ventricle to the pulmonary artery
is unavoidable? 
Finally, stent placement within conduits has generated
much enthusiasm over the past 3 or 4 years. Having removed
many very heavily calcified conduits and rigid porcine valves
containing Dacron conduits, I find it difficult to imagine that
stents can have much of an impact on such conduits. How
effective do you think stents are in prolonging the life of a
conduit? If you do perceive a benefit, can you estimate how
great that benefit might be? 
Dr Caldarone. Thank you, Dr Jonas. Without question, the
indications for a pulmonary valve replacement varied across
the time spectrum of the study; over 30 years, the diagnostic
modalities certainly would have changed considerably. It
would be difficult for me to put a number on the percentage
of systemic blood pressure found in the right ventricle that
would trigger a valve replacement. I am sure that varied
among surgeons and over time. 
One of the problems with such a large database is that fine
detail and the smaller decision-making with individual sub-
sets are lost. Therefore, I cannot give you a direct answer
regarding right ventricular pressure. In general, I would say
right ventricular pressures two-thirds to three-quarters sys-
temic was generally used as a trigger for some sort of inter-
vention. How closely that was adhered to, though, would
require angiographic data on essentially all of the patients,
and we do not have that information in this study. 
Indications for valve placement for pulmonary insufficiency
in patients with tetralogy of Fallot who have had a transannular
patch are also evolving. At present, exercise capacity appears to
be a reasonable marker for timing valve placement, but I am
sure this indication also has evolved over the past 30 years. 
Stent placement for pulmonary valve or conduit stenosis is
1030 Caldarone et al The Journal of Thoracic and
Cardiovascular Surgery
December 2000
predicting pulmonary valve deterioration, which was the end
point we wanted to evaluate. We believed even more strong-
ly that the variables predictive of an early death after a pul-
monary valve replacement in, for instance, a neonate were
likely to be very different from factors that would determine
long-term pulmonary valve deterioration. For these reasons,
we did not use death as an end point. 
In the univariable analyses in each age subset, if we includ-
ed late death as an end point, there was no difference in the
results. If we included all deaths, a substantial number of
which were early deaths, the only effect was a clouding of the
database, which caused us to lose statistical significance in
individual age groups. We feel fairly confident that exclusion
of death as an end point was reasonable.
Dr Ludwig K. von Segesser (Lausanne, Switzerland). You
have clearly shown that repeated reoperations are an
increased risk for again having to replace the valves. What is
the place for a mechanical valve in an adult who has been
operated on, say, 5 times before? 
Dr Caldarone. In our series very few mechanical valves
had been inserted in the pulmonary circulation, and no device
had been implanted in more than 4 patients. Thus, we were
not able to analyze the survival of mechanical valve prosthe-
ses. In general, our experience with mechanical prostheses in
the pulmonary position has been poor.
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an interesting idea. We recently published a series in which
stents were used [Ovaert C, Caldarone CA, McCrindle BW.
Endovascular stent implantation for the management of post-
operative right ventricular outflow tract obstruction. J Thorac
Cardiovasc Surg 1999;118:886-93], and the conclusions of
that study were that stents could delay the ultimate valve or
conduit replacement for a short time, perhaps 50% for 4
years. If indeed our age relationship was true, then that would
suggest that any palliative procedure that could allow the
patient to get older would decrease the risk of failure of the
subsequent prosthetic valve replacement. The only way to test
that hypothesis would be to actually randomize patients
prospectively, and my inclination is that the theory probably
would not be validated. I do not think we would actually alter
the natural history of this imposed disease by delaying valve
replacement with stents. 
Sir Magdi Yacoub (London, England). I have a small com-
ment: the patients who died were censored. How many of
these patients had an autopsy, and what would the effect on
the statistics have been had you considered those patients as
valve failures as well? 
Dr Caldarone. In designing the study, we spent quite a bit
of time discussing whether to include late death as an end
point. Our sense was that the variables predictive of a late
death were liable to be somewhat different from the variables
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